Brower Piven Announces an Investigation of the Acquisition of Clinical Data, Inc. by Forest Laboratories, Inc.

STEVENSON, Md.--(BUSINESS WIRE)--The law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Clinical Data, Inc. (“Clinical Data”) (NASDAQ:CLDA) and other violations of state law by the Board of Directors of Clinical Data relating to the proposed acquisition of the company by Forest Laboratories, Inc. (“Forest”) (NYSE:FRX). The firm’s investigation seeks to determine whether Clinical Data’s Board breached their fiduciary duties by failing to maximize shareholder value.